A Phase 3 interventional study of GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 32 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-28.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 17th largest by enrollment, is the only one that started in 2015, is one of 22 in phase 3, and was the 16th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 1 started in 2015.
This study's enrollment of 430 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 20th largest by enrollment of the 37 interventional ones that give a count, is the only one that started in 2015, is one of 25 in phase 3, and was the 27th registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults ≥ 65 years of age with and without Zostavax® vaccination at least 5 years earlier.
The study will evaluate two parallel groups of 200 adults ≥ 65 YOA; one group (Prev-Zvax) with a previous Zostavax® vaccination at least 5 years earlier, versus the other group without a previous Zostavax® vaccination (No prev-Zvax). The goal of this study is to generate immunogenicity, safety and reactogenicity data for the respective vaccines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the No prev-Zvax group only:
For the Prev-Zvax group only:
Exclusion Criteria:
Acute disease and/or fever at the time of enrolment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects ≥ 65 years of age who received Zostavax vaccine ≥ 5 years earlier and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Subjects ≥ 65 years of age who never received Zostavax vaccine and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Drug page: Shingrix
2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations
Varicella Zoster Virus (VZV) gE Ab.Immunoglobulin G (IgG) was determined by Enzyme Linked Immunosorbent Assay (ELISA). Concentrations are presented as geometric mean concentrations (GMCs), expressed in milliinternational units per millilitre (mIU/mL). Geometric mean antibody concentrations were adjusted for group-matching variable.
Time frame: One month after dose 2, at Month 3
Number of Subjects With Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = Occurrence of the symptom regardless of its intensity grade. Grade 3 pain = Significant pain at rest that prevented normal everyday activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During the 7-day (Days 0-6) period after each dose.
Number of Days With Solicited Local Symptoms
Solicited local symptoms were assessed during the 7-day (Days 0-6) period after each dose.
Time frame: During the 7-day (Days 0-6) period after each dose.
Number of Subjects With Solicited General Symptoms
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (included nausea, vomiting, diarrhea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\] . Any = Occurrence of the symptom regardless of its intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6) period after each dose.
Number of Days With Solicited General Symptoms
Solicited general symptoms were assessed during the 7-day (Days 0-6) period after each dose.
Time frame: During the 7-day (Days 0-6) period after each dose.
Number of Subjects With Any, Grade 3 and Related Unsolicited Symptoms (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: During the 30-day (Days 0-29) period after each dose.
Number of Subjects With Any and Related Serious Adverse Events (SAEs)
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE = SAE assessed by the investigator as related to the vaccination.
Time frame: From first vaccination (Month 0) up to 30 days post last vaccination (Month 3)
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: From first vaccination (Month 0) up to 30 days post last vaccination (Month 3)
Anti-gE Ab Concentrations
VZV gE IgG antibody concentrations were determined by ELISA. Concentrations are presented as geometric mean concentrations (GMCs), expressed in milliinternational units per millilitre (mIU/mL).
Time frame: At Months 0, 1, 3 and 14.
Frequencies of gE-specific Cluster of Differentiation 4 (CD4+) T-cells
gE-specific CD4+ T-cells, expressing at least two activation markers (from among interferon gamma \[IFN-γ\], interleukin-2 \[IL-2\], tumour necrosis factor alpha \[TNF-α\] and cluster of differentiation 40-ligand \[CD40L\]), as determined by in vitro Intracellular Cytokine Staining (ICS).
Time frame: At Months 0, 1, 3 and 14.
Number of Subjects With Any and Related SAEs
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE = SAE assessed by the investigator as related to the vaccination.
Time frame: From 30 days post last vaccination (Month 3) until study end at Month 14
Number of Subjects With Any pIMDs
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: From 30 days post last vaccination (Month 3) until study end at Month 14
| Milestone | GSK1437173A Group | Control Group |
|---|---|---|
| Started | 215 | 215 |
| Completed | 213 | 212 |
| Not completed | 2 | 3 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Migrated/moved from study area | 0 | 1 |
| Milestone | GSK1437173A Group | Control Group |
|---|---|---|
| Started | 215 | 215 |
| Completed | 210 | 204 |
| Not completed | 5 | 11 |
| Withdrew: Adverse event | 4 | 3 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Migrated/moved from study area | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Other-transfer of subject not completed | 0 | 1 |
Varicella Zoster Virus (VZV) gE Ab.Immunoglobulin G (IgG) was determined by Enzyme Linked Immunosorbent Assay (ELISA). Concentrations are presented as geometric mean concentrations (GMCs), expressed in milliinternational units per millilitre (mIU/mL). Geometric mean antibody concentrations were adjusted for group-matching variable.
| mIU/mL | GSK1437173A Group | Control Group |
|---|---|---|
| Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations | 50522.9 (44347.4 to 57558.4) | 48589.4 (42649.4 to 55356.6) |
Assessed solicited local symptoms were pain, redness and swelling. Any = Occurrence of the symptom regardless of its intensity grade. Grade 3 pain = Significant pain at rest that prevented normal everyday activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Any Pain, Dose 1 | 171 | 159 |
| Grade 3 Pain, Dose 1 | 8 | 7 |
| Any Redness, Dose 1 | 69 | 48 |
| Grade 3 Redness, Dose 1 | 3 | 2 |
| Any Swelling, Dose 1 | 29 | 21 |
| Grade 3 Swelling, Dose 1 | 1 | 0 |
| Any Pain, Dose 2 | 163 | 161 |
| Grade 3 Pain, Dose 2 | 5 | 10 |
| Any Redness, Dose 2 | 69 | 53 |
| Grade 3 Redness, Dose 2 | 6 | 2 |
| Any Swelling, Dose 2 | 29 | 27 |
| Grade 3 Swelling, Dose 2 | 0 | 1 |
Solicited local symptoms were assessed during the 7-day (Days 0-6) period after each dose.
| Days | GSK1437173A Group | Control Group |
|---|---|---|
| Any Pain, Dose 1 | 3.0 (2.0 to 4.0) | 2.0 (2.0 to 3.0) |
| Any Redness, Dose 1 | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 4.0) |
| Any Swelling, Dose 1 | 2.0 (2.0 to 3.0) | 3.0 (2.0 to 4.0) |
| Any Pain, Dose 2 | 2.0 (2.0 to 3.0) | 2.0 (2.0 to 3.0) |
| Any Redness, Dose 2 | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 5.0) |
| Any Swelling, Dose 2 | 2.0 (1.0 to 4.0) | 2.0 (1.0 to 4.0) |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (included nausea, vomiting, diarrhea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\] . Any = Occurrence of the symptom regardless of its intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Any Fatigue, Dose 1 | 69 | 59 |
| Grade 3 Fatigue, Dose 1 | 4 | 4 |
| Related Fatigue, Dose 1 | 62 | 48 |
| Any Gastro. int., Dose 1 | 31 | 14 |
| Grade 3 Gastro. int., Dose 1 | 2 | 2 |
| Related Gastro. int., Dose 1 | 24 | 9 |
| Any Headache, Dose 1 | 41 | 44 |
| Grade 3 Headache, Dose 1 | 4 | 1 |
| Related Headache, Dose 1 | 34 | 34 |
| Any Myalgia, Dose 1 | 47 | 42 |
| Grade 3 Myalgia, Dose 1 | 2 | 5 |
| Related Myalgia, Dose 1 | 41 | 37 |
| Any Shivering, Dose 1 | 25 | 17 |
| Grade 3 Shivering, Dose 1 | 2 | 1 |
| Related Shivering, Dose 1 | 22 | 16 |
| Any Fever, Dose 1 | 15 | 17 |
| Grade 3 Fever, Dose 1 | 0 | 0 |
| Related Fever, Dose 1 | 12 | 14 |
| Any Fatigue, Dose 2 | 91 | 93 |
| Grade 3 Fatigue, Dose 2 | 9 | 11 |
| Related Fatigue, Dose 2 | 85 | 84 |
| Any Gastro. int., Dose 2 | 30 | 27 |
| Grade 3 Gastro. int., Dose 2 | 0 | 0 |
| Related Gastro. int., Dose 2 | 30 | 22 |
| Any Headache, Dose 2 | 62 | 66 |
| Grade 3 Headache, Dose 2 | 2 | 3 |
| Related Headache, Dose 2 | 57 | 58 |
| Any Myalgia, Dose 2 | 61 | 53 |
| Grade 3 Myalgia, Dose 2 | 6 | 5 |
| Related Myalgia, Dose 2 | 56 | 51 |
| Any Shivering, Dose 2 | 36 | 26 |
| Grade 3 Shivering, Dose 2 | 4 | 3 |
| Related Shivering, Dose 2 | 34 | 24 |
| Any Fever, Dose 2 | 26 | 19 |
| Grade 3 Fever, Dose 2 | 0 | 0 |
| Related Fever, Dose 2 | 24 | 18 |
Solicited general symptoms were assessed during the 7-day (Days 0-6) period after each dose.
| Days | GSK1437173A Group | Control Group |
|---|---|---|
| Any Fatigue, Dose 1 | 1.0 (1.0 to 3.0) | 1.0 (1.0 to 3.0) |
| Any Gastrointestinal symptoms, Dose 1 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
| Any Headache, Dose 1 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
| Any Myalgia, Dose 1 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) |
| Any Shivering, Dose 1 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 2.0) |
| Any Temperature, Dose 1 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| Any Fatigue, Dose 2 | 1.0 (1.0 to 2.0) | 2.0 (1.0 to 3.0) |
| Any Gastrointestinal symptoms, Dose 2 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 2.0) |
| Any Headache, Dose 2 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
| Any Myalgia, Dose 2 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
| Any Shivering, Dose 2 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| Any Temperature, Dose 2 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Any AEs | 81 | 54 |
| Grade 3 AEs | 14 | 5 |
| Related AEs | 13 | 13 |
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE = SAE assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Any SAEs | 4 | 4 |
| Related SAEs | 0 | 0 |
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) | 2 | 1 |
VZV gE IgG antibody concentrations were determined by ELISA. Concentrations are presented as geometric mean concentrations (GMCs), expressed in milliinternational units per millilitre (mIU/mL).
| mIU/mL | GSK1437173A Group | Control Group |
|---|---|---|
| At Month 0 | 1784.3 (1572.9 to 2024.1) | 1408.5 (1203.3 to 1648.8) |
| At Month 1 | 29959.0 (26633.6 to 33699.6) | 25233.7 (22072.3 to 28848.0) |
| At Month 3 | 49327.2 (45388.2 to 53608.1) | 51618.5 (47224.8 to 56420.9) |
| At Month 14 | 17783.6 (16077.1 to 19671.4) | 15784.1 (14180.2 to 17569.4) |
gE-specific CD4+ T-cells, expressing at least two activation markers (from among interferon gamma \[IFN-γ\], interleukin-2 \[IL-2\], tumour necrosis factor alpha \[TNF-α\] and cluster of differentiation 40-ligand \[CD40L\]), as determined by in vitro Intracellular Cytokine Staining (ICS).
| CD4+ T-cells/million T-cells | GSK1437173A Group | Control Group |
|---|---|---|
| At Month 0 | 89.09 ± 99.73 | 90.88 ± 97.5 |
| At Month 1 | 562.17 ± 532.58 | 534.57 ± 523.97 |
| At Month 3 | 2946.02 ± 2088.48 | 2843.89 ± 2111.54 |
| At Month 14 | 1290.98 ± 1181.89 | 1126.44 ± 1012.28 |
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE = SAE assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Any SAEs | 15 | 18 |
| Related SAEs | 0 | 0 |
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Number of Subjects With Any pIMDs | 1 | 3 |
Collected over Solicited local and general AEs were assessed during a 7-day follow-up period (Days 0-6) after each vaccination visit. Unsolicited AEs were assessed for a period of 30 days (Days 0-29) after each vaccination visit. SAEs were assessed from the first receipt of the study vaccine (Month 0) up to study end (Month 14).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1437173A Group | 2/215 (0.9%) | 18/215 (8.4%) | 199/215 (92.6%) |
| Control Group | 3/215 (1.4%) | 22/215 (10.2%) | 197/215 (91.6%) |
| Event | GSK1437173A Group | Control Group |
|---|---|---|
| Atrial fibrillationCardiac disorders | 2/215 | 0/215 |
| Coronary artery diseaseCardiac disorders | 0/215 | 2/215 |
| CellulitisInfections and infestations | 2/215 | 1/215 |
| DehydrationMetabolism and nutrition disorders | 1/215 | 2/215 |
| LeukocytosisBlood and lymphatic system disorders | 0/215 | 1/215 |
| ArrhythmiaCardiac disorders | 0/215 | 1/215 |
| Atrioventricular blockCardiac disorders | 0/215 | 1/215 |
| Cardiac arrestCardiac disorders | 0/215 | 1/215 |
| Myocardial infarctionCardiac disorders | 0/215 | 1/215 |
| PalpitationsCardiac disorders | 1/215 | 0/215 |
| Event | GSK1437173A Group | Control Group |
|---|---|---|
| PainGeneral disorders | 189/215 | 181/215 |
| FatigueGeneral disorders | 114/215 | 111/215 |
| ErythemaSkin and subcutaneous tissue disorders | 96/215 | 73/215 |
| HeadacheNervous system disorders | 80/215 | 89/215 |
| MyalgiaMusculoskeletal and connective tissue disorders | 82/215 | 78/215 |
| ChillsGeneral disorders | 51/215 | 37/215 |
| SwellingGeneral disorders | 50/215 | 37/215 |
| Gastrointestinal disorderGastrointestinal disorders | 49/215 | 38/215 |
| PyrexiaGeneral disorders | 36/215 | 32/215 |
| Age, Continuous(Years) | GSK1437173A Group | Control Group | Total |
|---|---|---|---|
| Mean | 71.1 ± 4.5 | 70.8 ± 4.6 | 70.9 ± 4.6 |
| Sex: Female, Male(Participants) | GSK1437173A Group | Control Group | Total |
|---|---|---|---|
| Female | 109 | 111 | 220 |
| Male | 106 | 104 | 210 |
| Race/Ethnicity, Customized(Participants) | GSK1437173A Group | Control Group | Total |
|---|---|---|---|
| White - Caucasian / European Heritage — White - Caucasian / European Heritage | 215 | 215 | 430 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Dec 2015 to primary completion in Aug 2016, 8 months.
Results were first posted in Sep 2017, 1 year after primary completion.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 8 months is below that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix